Publications by authors named "A A van der Klaauw"
Article Synopsis
- Elderly individuals (70 years and older) show weaker antibody responses to a COVID-19 booster compared to younger people after receiving an initial two-dose vaccine series with AZD1222 and a third mRNA booster.
- The elderly have a specific type of B cells (anomalous spike-specific B cells) that may impair their ability to neutralize the virus effectively after the booster.
- Interestingly, when elderly individuals receive three doses of mRNA vaccines, their antibody responses are comparable to those younger than 70, suggesting that different vaccine technologies influence immune memory formation.
Obesity is associated with an increased risk of severe Coronavirus Disease 2019 (COVID-19) infection and mortality. COVID-19 vaccines reduce the risk of serious COVID-19 outcomes; however, their effectiveness in people with obesity is incompletely understood. We studied the relationship among body mass index (BMI), hospitalization and mortality due to COVID-19 among 3.
View Article and Find Full Text PDFBackground: COV-BOOST is a multicentre, randomised, controlled, phase 2 trial of seven COVID-19 vaccines used as a third booster dose in June 2021. Monovalent messenger RNA (mRNA) COVID-19 vaccines were subsequently widely used for the third and fourth-dose vaccination campaigns in high-income countries. Real-world vaccine effectiveness against symptomatic infections following third doses declined during the Omicron wave.
View Article and Find Full Text PDFSafety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial.
Lancet Infect Dis
August 2022
Background: Some high-income countries have deployed fourth doses of COVID-19 vaccines, but the clinical need, effectiveness, timing, and dose of a fourth dose remain uncertain. We aimed to investigate the safety, reactogenicity, and immunogenicity of fourth-dose boosters against COVID-19.
Methods: The COV-BOOST trial is a multicentre, blinded, phase 2, randomised controlled trial of seven COVID-19 vaccines given as third-dose boosters at 18 sites in the UK.